13F Holdings
中文EN

SABS SAB Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1833214 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-40.9%
TTM net income YoY19.2%
TTM EPS YoY51.8%
Revenue 3-yr CAGR-72.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,244.9%
Net margin-2,579.0%
FCF margin-2,618.6%
EBITDA margin-2,895.0%

Returns

ROE-81.9%
ROA-53.2%
ROIC (approx.)-380.8%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets41.2%
Debt / equity0.00x
Current ratio2.98x
Interest coverage-134.77x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue25.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$1.32M$2.24M$23.90M$60.88M
R&D expense$34.35M$30.25M$16.52M$36.44M$57.18M
SG&A expense$14.60M$13.98M$23.80M$16.38M$17.09M
Operating income-$48.95M-$42.91M-$38.08M-$28.92M-$13.39M
Interest expense$240,664$318,401$315,284$301,584$294,459
Pretax income$13.27M—-$42.19M-$18.72M-$17.14M
Income tax$0$0$0$25,629$0
Net income$13.27M-$34.11M-$42.19M-$18.74M-$17.14M
EBITDA-$45.96M-$38.20M-$34.42M-$25.75M-$11.90M
EPS (basic)0.22-3.68-7.64-4.31-0.63
EPS (diluted)-0.79-3.68-7.64-4.31-0.63
Weighted avg. shares (diluted)61.34M9.26M5.52M4.35M27.34M
Balance sheet
Cash & equivalents$10.50M$8.90M$56.57M$15.05M$33.21M
Short-term investments$86.09M$11.86M$0——
Receivables——$0$5.56M$8.01M
Current assets$101.05M$23.79M$58.91M$22.10M$50.19M
PP&E, net$13.31M$15.37M$19.74M$23.25M$24.31M
Total assets$172.81M$44.20M$83.94M$50.90M$81.14M
Current liabilities$10.68M$7.98M$10.81M$14.99M$26.46M
Total liabilities$21.32M$18.23M$26.64M$19.85M$42.59M
Shareholders' equity$151.50M$25.97M$57.30M$31.06M$38.55M
Shares outstanding47.61M9.29M9.23M5.04M43.49M
Cash flow statement
Operating cash flow-$44.78M-$34.29M-$25.12M-$23.46M$1.99M
Capital expenditure$933,156$337,262$197,154$2.17M$10.94M
Free cash flow-$45.71M-$34.63M-$25.32M-$25.63M-$8.96M
Investing cash flow-$121.71M-$11.96M-$152,704-$2.09M-$10.94M
Financing cash flow$168.30M-$1.17M$66.77M$1.05M$35.89M
Depreciation & amortization$2.99M$4.71M$3.65M$3.17M$1.49M
Stock-based compensation$5.21M$2.94M$2.42M$2.67M$2.31M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.